PYC Therapeutics announced the first results from its non-Good Laboratory Practice (non-GLP) studies which evaluated the ability of its proprietary RNA therapeutic modality to reach high value target cells within the retina of rabbits. These results represent the first assessment of PYC's technology in an eye that resembles that of a human in both structure and size and provide encouraging evidence in support of PYC's upcoming clinical trials which are anticipated to begin in ~12 months time. PYC's RNA therapeutic modality: i) reached all layers of the retina following intravitreal administration in the rabbit eye; ii) reached the nucleus of the target cell type in the Company's co-lead program for Retinitis Pigmentosa type 11; and iii) successfully engaged the target pre-messenger RNA resulting in the desired change in the target messenger RNA. Today's results, if accompanied by successful outcomes in PYC's ongoing safety and tolerability studies (results expected in Fourth Quarter 2021), should represent comprehensive non-clinical validation of PYC's drug delivery technology in the eye1. Effective drug delivery to the retina remains one of the most significant unresolved challenges in ophthalmology 2 and overcoming this problem holds the promise of improved patient outcomes across a broad spectrum of blinding eye diseases. The results position PYC on the cusp of the transition to a clinical-stage company with a differentiated and scalable platform technology that overcomes a fundamental challenge in the development of precision medicines.